Melanoma Archives - Wiser Healthcare

Correction: Exploring the Integration of Environmental Impacts in the Cost Analysis of the Pilot MEL-SELF Trial of Patient-Led Melanoma Surveillance – Jake T. W. Williams et al.

Lucia Marcello2024-02-13T13:25:11+11:00Cancer, Carbon neutral, Correction, Melanoma, Patient-led surveillance, Publications, Sustainable health care|

In this article the Methods section of the Abstract was incorrectly given as “Economic costs were calculated alongside a randomised trial using standard cost analysis methodology from a societal perspective. Environmental impacts were calculated using a type of carbon footprinting methodology called process-based life cycle [...]

Ecological study estimating melanoma overdiagnosis in the USA using the lifetime risk method – Adewole S. Adamson et al.

Lucia Marcello2024-02-11T15:27:31+11:00Cancer, Melanoma, Overdiagnosis, Publications, Risk|

The objective of this study is to quantify the proportion of melanoma diagnoses (invasive and in situ) in the USA that might be overdiagnosed. In this ecological study, incidence and mortality data were collected from the Surveillance, Epidemiology and End Results 9 registries database. DevCan [...]

Prognosis for people with multiple primary melanomas compared with a single primary melanoma – Yuan Ni et al.

Lucia Marcello2024-02-11T13:36:48+11:00Cancer, Melanoma, Publications|

To the Editor: People with a history of melanoma have a higher risk of developing subsequent primary melanomas than the general population; however, a difference in outcome between those with multiple primary melanomas (MPMs) and a single primary melanoma (SPM) is not established. Using a [...]

Long-term cost-effectiveness of a melanoma prevention program using genomic risk information compared with standard prevention advice in Australia – Chi Kin Law et al.

Lucia Marcello2024-02-09T15:50:06+11:00Cancer, Genetic testing, Melanoma, Precision medicine, Publications|

Evidence indicates that a melanoma prevention program using personalized genomic risk provision and genetic counseling can affect prevention behaviors, including reducing sunburns in adults with no melanoma history. This analysis evaluated its longer-term cost-effectiveness from an Australian health system perspective.

Telehealth follow-up consultations for melanoma patients during the COVID-19 pandemic: Patient and clinician satisfaction – Ali Al-Rikaby et al.

Lucia Marcello2024-04-06T14:51:33+11:00Cancer, COVID-19, Health policy, Health professionals, Insurance, Melanoma, Publications, Virtual Care/Telehealth|

The COVID-19 pandemic caused rapid implementation of telehealth for melanoma follow-up care in Australia. This study explores Australian melanoma patients and clinicians' level of satisfaction with telehealth.

Acceptability of a Hypothetical Reduction in Routinely Scheduled Clinic Visits Among Patients With History of a Localized Melanoma (MEL-SELF): Pilot Randomized Clinical Trial – Dorothy Drabarek, Deonna Ackermann, Ellie Medcalf, Katy J L Bell

Krista Verlis2023-10-23T15:06:48+11:00Melanoma, Patient-led surveillance, Publications|

Participants suggested that prerequisites for a reduction in routinely scheduled visits with melanoma doctors would include that sufficient time had elapsed since the previous diagnosis without a new primary melanoma or recurrence, an unscheduled appointment could be made at short notice if the patient noticed [...]

Strategies to Improve Adherence to Skin Self-examination and Other Self-management Practices in People at High Risk of Melanoma – A Scoping Review of Randomized Clinical Trials – Deonna M. Ackermann et al.

Lucia Marcello2023-04-14T13:43:26+10:00Cancer, Melanoma, Patient-led surveillance, Publications, Screening|

Adherence, both in research trials and in clinical practice, is crucial to the success of interventions. There is limited guidance on strategies to increase adherence and the measurement and reporting of adherence in trials of melanoma self-management practices.

Melanoma overdiagnosis: why it matters and what can be done about it – Katy Bell & Tamar Nijsten

Thomas Dakin2022-09-07T15:36:33+10:00Cancer, Melanoma, Overdiagnosis, Publications|

Cancer screening aims to reduce morbidity and mortality through early detection of preclinical disease. These potential benefits must be weighed against potential harms from diagnostic procedures, induced anxiety, false-positive or false-negative results and the detection of ‘indolent’ cancers, otherwise known as overdiagnosis.

Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (MelCOR): A modified Delphi study – Dale Jobson et al.

Thomas Dakin2022-07-11T16:02:10+10:00Cancer, Melanoma, Publications|

This study aimed to formally develop valid clinical quality indicators for the diagnosis and early management of cutaneous melanoma as an important step in creating the registry.

Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow up? Statistical analysis plan for the MEL-SELF randomised controlled trial –

Thomas Dakin2022-07-11T15:18:02+10:00Melanoma, Publications|

The primary trial aim is to determine if patient led-surveillance compared to clinician-led surveillance increases the proportion of participants who are diagnosed with a new primary or recurrent melanoma at a fast-tracked unscheduled clinic visit.

Melanoma

Staff Intranet